{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SML95FK06I
| verifiedrevid = 462249130
| IUPAC_name        = ''N'''-[(8α)-1,6-dimethylergolin-8-yl)-''N'',''N''-dimethylsulfamide
| image             = Mesulergine.svg
| index_label =
| index2_label = [<sup>3</sup>H]mesulergine
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3/t13-,15+,17+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JLVHTNZNKOSCNB-YSVLISHTSA-N
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 64795-35-3
| ATC_prefix        = 
| ATC_suffix        = 
| PubChem           = 68848
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 73378
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 462903
| IUPHAR_ligand2 = 232
| IUPHAR_ligand = 206
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID      = 62081
| C=18 | H=26 | N=4 | O=2 | S=1
| molecular_weight  = 362.49 g/mol
| smiles = O=S(=O)(N(C)C)N[C@H]2C[C@@H]3c4cccc1c4c(cn1C)C[C@H]3N(C2)C
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_category= 
| legal_status      = 
| routes_of_administration = 
}}

'''Mesulergine''' is a [[psychoactive drug]] of the [[ergoline]] [[chemical class]] that acts on [[serotonin receptor|serotonin]] and [[dopamine receptor]]s.<ref name="pmid6855451">{{cite journal | author = Closse A | title = [<sup>3</sup>H]-Mesulergine, a selective ligand for serotonin-2 receptors | journal = Life Sci. | volume = 32 | issue = 21 | pages = 2485–95 |date=May 1983 | pmid = 6855451 | doi = 10.1016/0024-3205(83)90375-2| url = }}</ref><ref name="pmid6230246">{{cite journal | author = Markstein R | title = Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors | journal = Eur. J. Pharmacol. | volume = 95 | issue = 1-2 | pages = 101–7 |date=November 1983 | pmid = 6230246 | doi = 10.1016/0014-2999(83)90272-8 | url = }}</ref>

The compound had entered clinical trials for the treatment of [[Parkinson's disease]]; however, further development was halted due to adverse [[histology|histological]] abnormalities in rats.<ref name="pmid3517235">{{cite journal |vauthors=Dupont E, Mikkelsen B, Jakobsen J | title = Mesulergine in early Parkinson's disease: a double blind controlled trial | journal = J. Neurol. Neurosurg. Psychiatr. | volume = 49 | issue = 4 | pages = 390–5 |date=April 1986 | pmid = 3517235 | pmc = 1028763 | doi = 10.1136/jnnp.49.4.390| url = }}</ref>

== See also ==
* [[Metergoline]]

== References ==
{{Reflist|2}}

{{Dopaminergics}}
{{Serotonergics}}
{{Ergolines}}

[[Category:Dopamine agonists]]
[[Category:Serotonin antagonists]]
[[Category:Ergolines]]


{{nervous-system-drug-stub}}